Coty's Q4 Beat Overshadowed by Another 'Transition Year' and Consumer Beauty Strategic Review

What happened

Coty reported a Q4 revenue beat, but weak guidance and management's characterization of FY2027 as another 'transition year' reveal deeper structural issues. The Consumer Beauty division, which has been persistently loss-making, is now under strategic review with potential divestitures or spin-offs, though execution risk looms until any deal closes. The latest 10-K already highlights high leverage (net debt/EBITDA 4.2x, interest coverage ~1.1x) and a FY25 GAAP net loss driven by impairments and derivative losses. Despite the revenue beat, the lack of a clear turnaround in like-for-like sales trends and recurring strategic churn undermine confidence in near-term stabilization. Shares remain near 52-week lows, trading below the DCF estimate, as the market discounts balance-sheet and earnings volatility.

Implication

The Q4 beat is not a reliable signal of improvement given weak guidance and the lack of FY2027 visibility, so any near-term results should be treated with caution. The Consumer Beauty strategic review could unlock value if a divestiture or partnership is executed at a reasonable price, but the history of failed turnarounds and persistent losses suggests high execution risk. Balance sheet health remains a critical concern, with leverage at 4.2x net debt/EBITDA and interest coverage barely above 1x, leaving little room for error if cash flow disappoints. Investors should monitor prestige fragrance sell-out trends, which are the core growth engine, and any progress on cost reduction and tariff mitigation, as these will determine whether the stock can re-rate. Until there is clear evidence of like-for-like revenue growth, margin recovery, and debt reduction, the stock is more likely to remain range-bound or decline further, making the current valuation an insufficient margin of safety.

Thesis delta

The WAIT stance is maintained, but the news adds a negative twist: management's admission of another 'transition year' signals that previous restructuring efforts have not yet yielded a durable improvement. The strategic review of Consumer Beauty, while potentially value-accretive, introduces uncertainty and execution risk that further delays any potential upgrade. Consequently, the thesis remains unchanged: investors should wait for evidence of stabilization and deleveraging before committing capital.